

1 Comparative efficacy of tocilizumab and baricitinib in COVID-19 treatment: a  
2 retrospective cohort study

3 **Running Title:** Tocilizumab and baricitinib efficacy in COVID-19

4 Yuichi Kojima<sup>a</sup>, Sho Nakakubo<sup>a\*</sup>, Keisuke Kamada<sup>a,b,c</sup>, Yu Yamashita<sup>a,d</sup>, Nozomu Takei<sup>a</sup>,  
5 Junichi Nakamura<sup>a</sup>, Munehiro Matsumoto<sup>a</sup>, Hiroshi Horii<sup>a</sup>, Kazuki Sato<sup>a</sup>, Hideki Shima<sup>a</sup>,  
6 Masaru Suzuki<sup>a</sup>, Satoshi Konno<sup>a</sup>

7

8 <sup>a\*</sup> Department of Respiratory Medicine, Faculty of Medicine and Graduate School of  
9 Medicine, Hokkaido University, North 15 West 7, Kita-ku, Sapporo, 060-8638, Japan.

10 <sup>b</sup> Department of Mycobacterium Reference and Research, The Research Institute of  
11 Tuberculosis, Japan Anti-Tuberculosis Association, 3-1-24, Matsuyama Kiyose, Tokyo,  
12 Japan.

13 <sup>c</sup> Department of Epidemiology and Clinical Research, The Research Institute of  
14 Tuberculosis, Japan Anti-Tuberculosis Association, 3-1-24, Matsuyama Kiyose, Tokyo,  
15 Japan

16 <sup>d</sup> Department of Respiratory Medicine 1, Obihiro Kosei General Hospital, Obihiro,  
17 Japan.

18

19 Corresponding Author

20 Sho Nakakubo

21 Department of Respiratory Medicine, Faculty of Medicine and Graduate School of

22 Medicine, Hokkaido University, North 15 West 7, Kita-ku, Sapporo, 060-8638, Japan.

23 E-mail: shonakakubo@pop.med.hokudai.ac.jp

24 Tel: +81-11-706-5911

25

26 **Abbreviations**

27 BMI: body mass index

28 BRT: baricitinib

29 CI: Confidence interval

30 COVID-19: Coronavirus disease, 2019

31 CRP: C-reactive protein

32 IQR: interquartile rage

33 JAK: Janus kinase inhibitor

34 KL-6: Krebs von den Lungen-6.

35 LDH: lactate dehydrogenase

36 OR: odds ratio

37 PCR: Polymerase chain reaction

38 SARS-CoV-2: severe acute respiratory syndrome coronavirus 2

39 TCZ: tocilizumab

40 WBC: White blood cell

41

42

43 **Summary**

44 Background

45 Although biological agents, tocilizumab and baricitinib, have been shown to improve  
46 the outcomes of patients with COVID-19, a comparative evaluation has not been  
47 performed.

48 Methods

49 A retrospective, single-center study was conducted using the data of patients with  
50 COVID-19 admitted to the Hokkaido University hospital between April 2020 and  
51 September 2021, who were treated with tocilizumab or baricitinib. The clinical  
52 characteristics of patients who received each drug were compared. Univariate and  
53 multivariate logistic regression models were performed against the outcomes of  
54 all-cause mortality and the improvement in respiratory status. The development of  
55 secondary infection events was analyzed using the Kaplan-Meier analysis and the  
56 log-rank test.

57 Results

58 The use of tocilizumab or baricitinib was not associated with all-cause mortality  
59 and the improvement in respiratory status within 28 days of drug administration. Age,  
60 chronic renal disease, and comorbid respiratory disease were independent prognostic

61 factors for all-cause mortality, while anti-viral drug use and severity of COVID-19  
62 at baseline were associated with the improvement in respiratory status. There was  
63 no significant difference in the infection-free survival between patients treated  
64 with tocilizumab and those with baricitinib.

65 Conclusion

66 There were no differences in efficacy and safety between tocilizumab and baricitinib  
67 for the treatment of COVID-19.

68 **Keywords:** COVID-19, biological agents, tocilizumab, baricitinib, retrospective  
69 study.

70

71 **Introduction**

72 Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome  
73 coronavirus 2 (SARS-CoV-2), continues to spread worldwide. As various treatment  
74 methods have been established and vaccination has progressed, the situation  
75 surrounding COVID-19 has entered a new phase. However, the optimal treatment for  
76 severe COVID-19 continues to be explored.

77 Steroids were first identified to be effective in the treatment of severe COVID-19  
78 and are now considered as the standard treatment (1, 2). Following this, several  
79 studies were conducted to determine whether addition of biological agents to the  
80 standard treatment could improve prognosis. Tocilizumab (TCZ) is a monoclonal  
81 antibody against interleukin-6 receptor-alpha (3). Both REMAP-CAP and RECOVERY  
82 trials evaluated the add-on effect of TCZ to the standard of care in hospitalized  
83 patients with severe-to-critical COVID-19 and showed that TCZ reduces mortality or  
84 prolongs organ support-free days (4, 5). Baricitinib (BRT) is a Janus kinase (JAK)  
85 inhibitor with high selectivity for JAK1 and JAK2 molecules of the JAK family (6).

86 It has been observed initially in the ACTT-2 trial that BRT shortens the time to  
87 recovery, when used in combination with remdesivir in the treatment of severe COVID-19  
88 (7) . Further, in the COV-BARRIER trial, treatment with baricitinib, in addition to

89 standard care, was associated with reduced mortality in adults hospitalized with  
90 COVID-19 (8). A common finding among these trials was that both TCZ and BRT are  
91 particularly effective in reducing mortality in patients with a high demand for  
92 oxygen.

93 Based on the evidence, the current guidelines recommend that both TCZ and BRT be  
94 administered in combination with steroids to patients with severe COVID-19 requiring  
95 high-flow oxygen and non-invasive mechanical ventilation and those with rapidly  
96 increasing oxygen needs and systemic inflammation (9, 10). However, to our knowledge,  
97 no comparative study exists to verify the superiority of the efficacy of TCZ versus  
98 BRT against COVID-19; therefore, the priority among the two is not clearly stated  
99 in the current international recommendation (9).

100 Herein, we retrospectively analyzed the medical information of patients with COVID-19  
101 admitted to the Hokkaido University Hospital to compare whether the use of TCZ or  
102 BRT was associated with mortality, clinical improvement, and incidence of secondary  
103 infection.

104

105 **Patients and Methods**

106 Patients

107 This single-center, retrospective cohort study was approved by Hokkaido University  
108 Hospital Division of Clinical Research Administration (Research No. 020-0107) . The  
109 requirement for obtaining informed consent was waived by the relevant ethics  
110 committee due to the retrospective nature of the study. This study included patients  
111 with COVID-19 who were admitted to the Hokkaido University Hospital between April  
112 2020 and September 2021. All patients were confirmed to be positive for SARS-CoV-2  
113 by polymerase chain reaction (PCR). Among the patients, those treated with biological  
114 agents (TCZ or BRT) for COVID-19 were selected for the present analysis. Cases in  
115 which both drugs were administered during the course of treatment were excluded.

116

117 Data collection

118 The clinical data (age, sex, body mass index, history of smoking, history of  
119 vaccination, comorbidities, respiratory status and severity, days from the onset of  
120 COVID-19, treatment protocol laboratory data, and clinical outcome) were collected  
121 from medical records. We defined the severity of COVID-19 as follows: severity level  
122 1- hospitalized but not requiring supplemental oxygen; level 2- hospitalized and



123 requiring supplemental oxygen  $\leq 4$  L per minute (L/min) ; severity level 3- hospitalized  
124 and requiring oxygen therapy  $\geq 5$  L/min, including receiving nasal high-flow oxygen  
125 therapy, non-rebreather, or noninvasive mechanical ventilation; level 4- receiving  
126 invasive mechanical ventilation at administration. The reason for setting this  
127 severity classification was that in our hospital, the criteria for administering  
128 biological agents was when the oxygen administration rate deteriorated to 5 L/min  
129 or higher.

130 We set the following clinical endpoints: all-cause mortality, improvement in  
131 respiratory status, and development of secondary infection events within 28 days  
132 after administration of TCZ or BRT. Improvement in respiratory status was defined  
133 as a recovery in severity to level 1 or 2 after the initiation of TCZ or BRT. Secondary  
134 infection events included pneumonia, bacteremia, urinary tract infection, and fungal  
135 infection requiring antibiotic treatment,

136

137 Statistical analysis

138 Continuous data are expressed as median and interquartile range (IQR). Categorical  
139 data are expressed as absolute number and percentages. Wilcoxon rank sum test or  
140 Kruskal-Wallis test was used to compare differences in continuous variables, and

141 chi-square test or Fisher' s exact test was used to evaluate differences between  
142 categorical variables. Clinical outcomes including all-cause mortality, improvement  
143 in respiratory status, and development of secondary infection events, were analyzed  
144 using univariable and multivariate logistic regression models, with odds ratio (OR)  
145 and 95 % confidence intervals (CI). Variables with  $P < 0.1$  in the univariate analysis  
146 were entered into the multivariate models. Infection-free survival was evaluated by  
147 the Kaplan-Meier method with a log-rank test. All P-values were two-tailed, with  
148 statistical significance set at  $P < 0.05$ . JMP (SAS Institute Inc., Cary, NC, USA)  
149 were used for all statistical processing.

150 **Results**

151 Study population

152 A total of 459 patients were admitted to the Hokkaido University Hospital with the  
153 diagnosis of COVID-19 during the study period. Of these, 100 patients received  
154 biological agents for treating the symptoms of COVID-19. Sixty-four patients were  
155 treated with TCZ (TCZ group) and 34 with BRT (BRT group). Two patients were initially  
156 treated with BRT but switched to TCZ, who were excluded from the study (Figure 1).

157

158 Baseline characteristics

159 The median age of total patients (N=98) was 60.5 years, and 74.5 % were males (Table  
160 1). Compared with the TCZ group (n=64), BRT group (n=34) had lower age (58.5 vs. 65.5  
161 years, P=0.03) and lower prevalence of chronic heart disease (5.9% vs. 23.4%, P=0.03).  
162 There were no significant differences in sex, smoking history, immunosuppressive drug  
163 use, obesity, chronic kidney disease, diabetes mellitus, collagen disease,  
164 hypertension, and comorbid respiratory disease. Only one patient in BRT group was  
165 fully vaccinated with two doses of the vaccine against SARS-CoV-2. Days from the onset  
166 of illness to the administration of biological agents were not significantly  
167 different between the two groups (10 vs. 9 days, P=0.50). Analysis of blood samples

168 revealed that, compared to the BRT group, the TCZ group had a significantly lower  
169 eosinophil count and hemoglobin (0 vs. 0,  $P=0.047$ , 13.8 vs. 14.5,  $P=0.04$ ,  
170 respectively), higher levels of lactate dehydrogenase (LDH), krebs von den Lungen-6  
171 (KL-6), and D-dimer (540 vs. 470,  $P=0.02$ , 444 vs. 319,  $P=0.03$ , 1.5 vs. 1.0,  $P<0.01$ ,  
172 respectively).

173 Most of the patients in both the groups received steroid treatment for COVID-19 (98.4 %  
174 in TCZ and 97.1 % in BRT group). The TCZ group were administered heparin more  
175 frequently and antivirals less frequently than the BRT group (86.0 % vs. 67.7 %,  $P=0.03$ ,  
176 70.3 % vs. 88.2 %,  $P=0.046$ , respectively). Only one patient was treated with a  
177 combination of the monoclonal antibodies (casirivimab and imdevimab) in the BRT group.  
178 The severity of COVID-19 was similar in both groups at the time of initiating treatment  
179 with the biological agents, with severity level 3 or higher in 93.2 % of the patients  
180 in TCZ group and 85.3 % in BRT group.

181

182 Risk factors for death within 28 days after initiating treatment with biological  
183 agents

184 Among the group of patients administered biological agents ( $N=98$ ), univariate  
185 analysis showed that the use of TCZ was significantly associated with increased

186 all-cause mortality. Additionally, increased age, presence of chronic kidney disease,  
187 administration of biological agents at less than seven days from onset, and no  
188 antiviral drug use were significantly associated with all-cause mortality (Table 2).  
189 In multivariate analysis, older age (OR =1.10, 95 % confidence interval (CI) 1.00  
190 -1.21, P=0.02), presence of chronic kidney disease (OR = 43.10, 95 %CI 2.71 - 686.04,  
191 P=0.008), and early administration of biological agents from onset (OR = 18.09, 95 %CI  
192 1.70 -192.47, P=0.02) were shown to be independent risk factors for all-cause  
193 mortality within 28 days. In contrast, the use of TCZ was not an independent prognostic  
194 factor for death (OR = 13.28, 95 %CI 0.45 - 392.92, P=0.13) (Table 2).

195

196 Factors contributing to improvement in respiratory status

197 In the univariate logistic regression analysis, factors contributing significantly  
198 to the improvement of respiratory status were BRT use, young age, absence of chronic  
199 heart disease, chronic kidney disease or hypertension, more than seven days from onset  
200 to drug administration, and use of any anti-viral drug (Table 3). However, in  
201 multivariate analysis, BRT use was not a contributing factor (OR = 1.75, 95 %CI 0.35  
202 -8.67, P=0.50), while the use of the anti-viral drug was an independent contributing  
203 factor (OR =6.5, 95 %CI 1.13 - 37.56, P=0.04). Early administration of biological

204 agents was the risk factor that reduced the likelihood of improving the respiratory  
205 status (OR = 0.82, 95 %CI 0.02 - 0.40, P=0.002).

206

207 Development of secondary infection

208 The rates of acquiring any secondary infection in patients within 28 days after  
209 initiation of treatment with TCZ and BRT were 15.6 and 14.7%, respectively. Univariate  
210 analysis did not identify any factors associated with the development of secondary  
211 infection after initiation of treatment with biological agents (Supplementary table).

212 There was also no significant difference in infection-free survival (P=0.95) (Figure  
213 2).

214 **Discussion**

215 In this retrospective study, we compared the clinical characteristics between two  
216 groups of patients treated with TCZ and BRT for COVID-19. Multivariate analysis  
217 revealed that both the biological agents did not increase all-cause mortality within  
218 28 days of treatment initiation. Age, underlying diseases, and early administration  
219 of biological agents were independent risk factors for all-cause mortality. None of  
220 the two biological agents significantly contributed to improving the respiratory  
221 status within 28 days. Use of anti-viral drugs and late administration of biological  
222 agents significantly contributed to improvement in respiratory status. No  
223 significant difference was observed in the development of secondary infection within  
224 28 days after TCZ or BRT administration.

225

226 The results of this study showed that most of the patients who were treated with TCZ  
227 or BRT were also receiving steroid therapy. In addition, the severity of COVID-19  
228 at the time of initiating treatment with biological agents was not significantly  
229 different between the two groups. In our hospital, patients with COVID-19 who required  
230 oxygen are usually treated with steroids, and biological agents are additionally  
231 administered to patients with increased oxygen demand, based on the guideline

232 treatment plan (9, 10). Although the present study was retrospective, the strength  
233 of the study was that the baseline treatment and respiratory status of both groups  
234 are well matched.

235 According to the results of univariate analysis, TCZ seemed to increase the risk of  
236 28-day mortality, while not improving the respiratory status. However, it was not  
237 identified as a significant risk factor in multivariate analysis. The reason for this  
238 could be due to the existence of multiple confounding factors for the use of TCZ.

239 Comparison of clinical characteristics between the TCZ and BRT groups revealed an  
240 older median age and a higher proportion of patients with chronic diseases in the  
241 TCZ group, than in the BRT groups. Moreover, blood test results showed higher levels  
242 of LDH and D-dimer in the TCZ group than that in the BRT group. Advanced age and  
243 presence of underlying diseases are considered poor prognostic factors for COVID-19  
244 (11, 12). Higher levels of LDH and D-dimer are associated with increased mortality  
245 in COVID-19 and are known to be predictors of severe disease (13). Although we did  
246 not find a significant difference in the severity of COVID-19 based on respiratory  
247 status, TCZ group might have potentially been at a higher risk for critical course.  
248 TCZ was shown to be effective relatively earlier than BRT in the COVID-19 pandemic  
249 and was used earlier in clinical practice. In contrast, BRT became widely used in



250 Japan after approval for the treatment of COVID-19. In addition, backgrounds of the  
251 patients admitted to our hospital differed depending on the timing of spread of  
252 COVID-19. These circumstances might contribute to the bias in the clinical  
253 characteristics of the two groups.

254 Biological drugs are a risk factor for serious infection in rheumatoid arthritis (14).

255 Although the COVID-19 trials showed no difference in the incidence of infections in  
256 either TCZ or BRT groups, compared to that in the placebo (4, 8), one retrospective  
257 study showed that concomitant use of TCZ and methylprednisolone is a risk factor for  
258 bacteremia (15). Besides, whether there is a difference in the risk of developing  
259 infections between TCZ and BRT has not been evaluated earlier. In our study, we found  
260 no difference in the incidence of secondary infection between TCZ group and BRT group.

261 In addition, no risk factors were identified in the univariate analysis, which could  
262 be associated with the occurrence of secondary infection. Although we have not been  
263 able to verify whether the complications of infections had an impact on patient  
264 prognosis, neither biological drug seems to pose a significant risk of infection.

265

266 Given the fact that treatment with any of the two biological agents did not result  
267 in significantly different outcomes for patients, either TCZ or BRT can be selected

268 in terms of efficacy and safety. BRT is an oral drug that can be administered even  
269 if the intravenous route is difficult to secure, and it is easy to discontinue.  
270 Tocilizumab is an intravenous or subcutaneous drug that can be used by patients who  
271 have difficulty with oral intake and in those with severe renal dysfunction. The  
272 choice should be based on the characteristics of each drug in each individual patient.

273

274 Our study confirmed that the improvement of patients' respiratory status in COVID-19  
275 was similar with both biological agents. In contrast, we found that the use of  
276 anti-viral drugs was significantly associated with improvement in respiratory status  
277 within 28 days.

278 According to the clinical trial, remdesivir has been shown to shorten the time to  
279 recovery in patients hospitalized with COVID-19 and with evidence of pneumonia (16).

280 In contrast, several studies have failed to show clear efficacy (17-19); the efficacy  
281 of remdesivir as a single agent or adjunctive drug for standard care may be limited.

282 Based on the results of our study, remdesivir may be an important drug that should  
283 essentially be administered to patients receiving biologic agents and steroids. This  
284 finding suggests the additive effect of remdesivir, which requires further  
285 investigation.

286

287 It is worth discussion that shorter time from the onset of illness to the  
288 administration of the biological drugs was an independent factor for poor prognosis.  
289 For both TCZ and BRT, earlier administration of drugs in the trials is associated  
290 with a greater reduction in the risk of death (5, 8). The reason of this apparently  
291 paradoxical observation was probably that the short time between the onset of symptoms  
292 and the administration of biological agents may reflect the rapid deterioration in  
293 respiratory status. In our hospital, biologic drugs are mostly administered to  
294 patients with increased oxygen demand and increased severity of illness. Worsening  
295 of respiratory status early in the course of the disease may be a prognostic factor  
296 that cancels out the benefit of early administration of biological drugs. The  
297 prognosis of patients who deteriorate rapidly after the onset of illness should be  
298 evaluated in future studies.

299

300 This study has several limitations. First, since the study was retrospective,  
301 prospective validation is needed to show the comparative efficacy of TCZ and BRT.  
302 Second, variant strains of SARS-CoV-2 and changes in healthcare availability that  
303 may affect patient outcomes were not validated in this study due to lack of data.

304 Lastly, the efficacy of using the biological agents as a standalone treatment for  
305 COVID-19 was not verified in this study. However, the efficacy of TCZ and BRT has  
306 already been proven in previous studies. Our study was conducted to suggest a more  
307 favorable treatment based on these evidence-based practices of using TCZ and BRT.

308

309 In conclusion, the use of TCZ versus BRT had no different impact on all-cause mortality,  
310 improvement in respiratory status, and the development of secondary infection in  
311 patients diagnosed with COVID-19. In light of our findings, both biological agents  
312 are expected to be equally safe and clinically effective, although future prospective  
313 studies are needed.

314

315 **Acknowledgements**

316 Not applicable.

317

318 **Conflict of Interest**

319 The authors state that they have no conflict of interest (COI).

320

321 **Funding**

322 This research did not receive any specific grant from funding agencies in the public,

323 commercial, or not-for-profit sectors.

324

325 **Ethical approval**

326 The research protocol was approved by the Ethics Committee of the Hokkaido University

327 Hospital (Research No. 020-0107) . The study was based on existing samples collected

328 in the course of routine practice and no additional risks are posed to patients.

329 Therefore, the individual' s informed consent was waived by the above ethics

330 committee. Informed consent for study participation was officially announced on the

331 website. All patient data were anonymized prior.

332

333 **Contributions**

334 YK and SN contributed to the study concept and design and interpretation, statistical  
335 analysis, and drafting of the manuscript. KK, YY, NT, JN, MM, HH, KS and HS contributed  
336 to the acquisition and interpretation of data. NT contributed to statistical analysis.  
337 YK, SN, and MM contributed to data acquisition. MS and SK contributed to the study  
338 concept and design, acquisition and interpretation of data, and finalization of the  
339 manuscript. All authors read and approved the final manuscript.

340

341 **References**

- 342 1. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone  
343 in Hospitalized Patients with Covid-19. *N Engl J Med.* 2021;384(8):693-704. DOI:  
344 10.1056/NEJMoa2021436
- 345 2. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect  
346 of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe  
347 Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.  
348 *Jama.* 2020;324(13):1307-16. DOI: 10.1001/jama.2020.17021
- 349 3. Kaly L, Rosner I. Tocilizumab - a novel therapy for non-organ-specific autoimmune  
350 diseases. *Best Pract Res Clin Rheumatol.* 2012;26(1):157-65. DOI:

351 10.1016/j.berh.2012.01.001

352 4. Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, et al.

353 Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. *N Engl J*

354 *Med.* 2021;384(16):1491-502. DOI: 10.1056/NEJMoa2100433

355 5. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a

356 randomised, controlled, open-label, platform trial. *Lancet.* 2021;397(10285):1637-45.

357 DOI: 10.1016/s0140-6736(21)00676-0

358 6. Emery P, Durez P, Hueber AJ, de la Torre I, Larsson E, Holzkämper T, et al.

359 Baricitinib inhibits structural joint damage progression in patients with rheumatoid

360 arthritis-a comprehensive review. *Arthritis Res Ther.* 2021;23(1):3. DOI:

361 10.1186/s13075-020-02379-6

362 7. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al.

363 Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. *N Engl J Med.*

364 2021;384(9):795-807. DOI: 10.1056/NEJMoa2031994

365 8. Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, et al. Efficacy

366 and safety of baricitinib for the treatment of hospitalised adults with COVID-19

367 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3

368 trial. *Lancet Respir Med.* 2021. DOI: 10.1016/s2213-2600(21)00331-3

- 369 9. Infectious Diseases Society of America Guidelines on the Treatment and  
370 Management of Patients with COVID-19. Infectious Diseases Society of America 2021;  
371 Version 5.6.0. Available at  
372 [https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-manage](https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/)  
373 [ment/](https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/). Accessed 1<sup>st</sup>, Dec. 2021.
- 374 10. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19)  
375 Treatment Guidelines. National Institutes of Health. Available at  
376 <https://www.covid19treatmentguidelines.nih.gov/>. Accessed 1<sup>st</sup>, Dec. 2021.
- 377 11. Gao YD, Ding M, Dong X, Zhang JJ, Kursat Azkur A, Azkur D, et al. Risk factors  
378 for severe and critically ill COVID-19 patients: A review. *Allergy*. 2021;76(2):428-55.  
379 DOI: 10.1111/all.14657
- 380 12. Matsunaga N, Hayakawa K, Terada M, Ohtsu H, Asai Y, Tsuzuki S, et al. Clinical  
381 epidemiology of hospitalized patients with COVID-19 in Japan: Report of the COVID-19  
382 REGISTRY JAPAN. *Clin Infect Dis*. 2020. DOI: 10.1093/cid/ciaa1470
- 383 13. Gallo Marin B, Aghagoli G, Lavine K, Yang L, Siff EJ, Chiang SS, et al. Predictors  
384 of COVID-19 severity: A literature review. *Rev Med Virol*. 2021;31(1):1-10. DOI:  
385 10.1002/rmv.2146
- 386 14. Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al.



- 387 Risk of serious infection in biological treatment of patients with rheumatoid arthritis:  
388 a systematic review and meta-analysis. *Lancet*. 2015;386(9990):258-65. DOI:  
389 10.1016/s0140-6736(14)61704-9
- 390 15. Badr M, De Oliveira B, Abdallah K, Nadeem A, Varghese Y, Munde D, et al. Effects  
391 of Methylprednisolone on Ventilator-Free Days in Mechanically Ventilated Patients with  
392 Acute Respiratory Distress Syndrome and COVID-19: A Retrospective Study. *J Clin Med*.  
393 2021;10(4). DOI: 10.3390/jcm10040760
- 394 16. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir  
395 for the Treatment of Covid-19 – Final Report. *N Engl J Med*. 2020;383(19):1813-26. DOI:  
396 10.1056/NEJMoa2007764
- 397 17. Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi  
398 D, et al. Remdesivir plus standard of care versus standard of care alone for the  
399 treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3,  
400 randomised, controlled, open-label trial. *Lancet Infect Dis*. 2021. DOI:  
401 10.1016/s1473-3099(21)00485-0
- 402 18. Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim  
403 Q, et al. Repurposed Antiviral Drugs for Covid-19 – Interim WHO Solidarity Trial Results.  
404 *N Engl J Med*. 2021;384(6):497-511. DOI: 10.1056/NEJMoa2023184

405 19. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with

406 severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.

407 Lancet. 2020;395(10236):1569-78. DOI: 10.1016/s0140-6736(20)31022-9

408

409

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

10 **Table 1. Comparison of baseline characteristics between tocilizumab and baricitinib groups.**

	Total (N=98)	Tocilizumab (n=64)	Baricitinib (n=34)	<i>P</i> -value
Characteristics				
Age (year)	60.5 (54.0, 70.3)	65.5 (54.3, 72.8)	58.5 (53.8, 64.3)	0.03
Sex(male)	73 (74.5)	46 (71.9)	27 (79.4)	0.42
Current smoker	16 (16.3)	9 (16.5)	7 (20.6)	0.41
BMI $\geq$ 30 (kg/m <sup>2</sup> ) *	25 (27.2)	18 (30.0)	7 (20.6)	0.40
Chronic heart disease	17 (17.4)	15 (23.4)	2 (5.9)	0.03
Chronic kidney disease	6 (6.1)	4 (6.3)	2 (5.9)	0.94
Diabetes mellitus	36 (36.7)	23 (35.9)	13 (38.2)	0.82
Any collagen disease	3 (3.1)	3 (4.7)	0 (0)	0.20
Hypertension	46 (46.9)	34 (53.1)	12 (35.3)	0.09
Any respiratory disease	8 (8.1)	6 (9.4)	2 (5.9)	0.55
Immunosuppressive drug regular use	3 (3.1)	2(3.1)	1 (2.9)	0.96
Twice vaccinated	1 (1.0)	0 (0)	1 (1.0)	0.14
Time from symptom onset to administration	9 (7, 12)	10 (7, 13)	9 (7, 11)	0.50
Time from onset to administration $\leq$ 7 days	29 (29.6)	19 (29.7)	10 (29.4)	0.98
Treatment				
Steroid	96 (98.0)	63 (98.4)	33 (97.1)	0.65
Heparin	78 (79.6)	55 (86.0)	23 (67.7)	0.03
Any anti-viral drug	75 (76.5)	45 (70.3)	30 (88.2)	0.046
Antibody cocktail therapy	1 (1.0)	0 (0)	1 (1.0)	0.14
Blood test at administration				
White blood cell (/ $\mu$ L)	7900 (5550, 8000)	(5400, 11075)	7700 (5600,	0.64

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

	10825)		10525)	
Neutrophils (/μL) **	6991 (4465, 9755)	7173 (4716, 10027)	6780 (4418, 9280)	0.53
Lymphocytes (/μL) **	611 (476, 908)	648 (440, 911)	608 (528, 852)	0.65
Eosinophil (/μL) **	0 (0, 0)	0 (0, 0)	0 (0, 8.3)	0.047
Hemoglobin (g/dL)	14.2 (12.9, 15.0)	13.8 (12.8, 15.0)	14.5 (13.9, 15.6)	0.04
Platelet (×10 <sup>4</sup> /μL)	19.0 (13.4, 25.9)	18.5 (12.7, 25.8)	20.7 (14.8, 26.4)	0.51
LDH (U/L)	512.5 (419.8, 647.5)	540 (438.8, 716.0)	470.5 (386.5, 603.5)	0.02
CRP (mg/mL)	7.1 (3.6, 11.2)	7.8 (3.9, 12.1)	5.8 (3.1, 9.4)	0.12
KL-6 (U/mL) ***	402 (289.5, 617.5)	444 (337, 705)	319 (240.3, 481.5)	0.03
Procalcitonin (ng/mL) ****	0.08 (0.05, 0.15)	0.08 (0.06, 0.12)	0.08 (0.05, 0.18)	0.97
Ferritin (ng/mL) *****	1125.5 (693.8, 1924.5)	1242.5 (745.3, 1966.3)	1080 (631.8, 1901)	0.44
D-dimer (μg/mL)*****	1.4 (1.0, 2.5)	1.5 (1.3, 3.1)	1.0 (0.8, 1.4)	<0.001
Severity				
1	1 (1)	1 (1.6)	0 (0)	
2	9 (9.2)	4 (6.3)	5 (14.7)	
3	76 (77.6)	49 (76.6)	27 (79.4)	
4	12 (12.2)	10 (15.6)	2 (5.9)	0.26

11 \*N=92 \*\*N=94 \*\*\*N=69 \*\*\*\*N=60 \*\*\*\*\*N=70 \*\*\*\*\*N=95

12 Data are shown as median (interquartile range) or number (%).

13 We defined COVID-19 disease severity at administration as follows: severity level 1, hospitalized but

14 not requiring supplemental oxygen; level 2, hospitalized and requiring supplemental oxygen ≤ 4 L per

15 minute (L/min); severity level 3, hospitalized and requiring oxygen therapy ≥ 5 L/min or receiving nasal

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

16 high-flow oxygen therapy, non-rebreather, or noninvasive mechanical ventilation; level 4, receiving

17 invasive mechanical ventilation at administration.

18 BMI, body mass index; CRP, C-reactive protein; KL-6, Krebs von den Lungen-6; LDH, lactate dehydrogenase.

19

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

20 **Table 2. Predicting factors for death within 28 days of administration in patients treated with**  
 21 **tocilizumab or baricitinib assessed using logistic regression analysis.**

Characteristic	Univariate		Multivariate	
	OR (95%CI)	<i>P</i> -value	OR (95%CI)	<i>P</i> -value
Tocilizumab use	8.41 (1.05–67.37)	0.045	13.28 (0.45–392.92)	0.13
Age (year)	1.10 (1.03–1.18)	0.004	1.10 (1.00–1.21)	0.04
Sex(male)	0.38 (0.12–1.26)	0.12		
Current smoker	0.35 (0.04–2.92)	0.33		
BMI $\geq$ 30 (kg/m <sup>2</sup> )	0.94 (0.27–3.30)	0.93		
Chronic heart disease	2.18 (0.59–8.03)	0.24		
Chronic kidney disease	16.40 (2.66–101.21)	0.003	43.10 (2.71–686.04)	0.008
Diabetes mellitus	1.35 (0.43–4.26)	0.61		
Any collagen disease	3.15 (0.27–37.31)	0.36		
Hypertension	2.29 (0.70–7.40)	0.17		
Any respiratory disease	4.31 (0.90–20.59)	0.07	1.85 (0.22–15.76)	0.57
Immunosuppressive drug regular use	3.15 (0.27–37.31)	0.36		
Time from onset to administration $\leq$ 7 days	5.76 (1.73–19.18)	0.004	18.09 (1.70–192.47)	0.02
<b>Treatment</b>				
Heparin	1.64 (0.34–7.98)	0.54		
Any anti-viral drug	0.34 (0.10–1.11)	0.07	0.16 (0.01–1.96)	0.15
<b>Blood test at administration</b>				
Lymphocytes ( $\times 10^3/\mu$ L)	0.36 (0.01–13.81)	0.58		
Platelet ( $\times 10^5/\mu$ L)	0.66 (0.35–1.24)	0.20		
LDH ( $\times 10^2$ U/L)	1.18 (0.88–1.59)	0.27		
CRP (mg/mL)	1.02 (0.92–1.13)	0.68		
KL-6 ( $\times 10^2$ U/mL)	1.06 (0.87–1.30)	0.57		
Procalcitonin (ng/mL)	1.36 (0.18–9.97)	0.76		
Ferritin ( $\times 10^3$ ng/mL)	0.37 (0.10–1.47)	0.16		

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

D-dimer ( $\mu$ g/mL)	0.10 (0.96-1.03)	0.82
-----------------------	------------------	------

Severity

1 or 2	(reference)	(reference )
3	1.52 (0.18-13.24)	0.70
4	1.80 (0.14-23.37)	0.65

22 We defined COVID-19 disease severity at administration as follows: severity level 1, hospitalized but  
23 not requiring supplemental oxygen; level 2, hospitalized and requiring supplemental oxygen  $\leq$  4 L per  
24 minute (L/min); severity level 3, hospitalized and requiring oxygen therapy  $\geq$  5 L/min or receiving nasal  
25 high-flow oxygen therapy, non-rebreather, or noninvasive mechanical ventilation; level 4, receiving  
26 invasive mechanical ventilation at administration.

27 BMI, body mass index; CI, Confidence interval; CRP, C-reactive protein; KL-6, Krebs von den Lungen-6;  
28 LDH, lactate dehydrogenase; OR, odds ratio.

29

30

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

31 **Table 3. Predicting factors for improvement in respiratory status within 28 days of administration in**  
 32 **patients treated with tocilizumab or baricitinib assessed using logistic regression analysis.**

	Univariate		Multivariate	
	OR (95%CI)	<i>P</i> -value	OR (95%CI)	<i>P</i> -value
Characteristics				
Baricitinib use	3.66 (1.14-11.76)	0.03	1.75 (0.35-8.67)	0.50
Age (year)	0.94 (0.89-0.98)	0.004	0.94 (0.88-1.01)	0.07
Sex(male)	1.55 (0.57-4.22)	0.39		
Current smoker	6.21 (0.78-49.65)	0.09	4.14 (0.28-60.37)	0.29
BMI $\geq 30$ (kg/m <sup>2</sup> )	1.46 (0.47-4.49)	0.50		
Chronic heart disease	0.27 (0.09-0.80)	0.03	0.40 (0.09-1.89)	0.25
Chronic kidney disease	0.15 (0.03-0.86)	0.03	0.12 (0.01-1.80)	0.13
Diabetes mellitus	1.04 (0.40-2.68)	0.93		
Any collagen disease	0.68 (0.07-9.12)	0.75		
Hypertension	0.39 (0.15-1.01)	0.047	0.84 (0.20-3.59)	0.82
Any respiratory disease	0.54 (0.12-2.44)	0.42		
Immunosuppressive drug regular use	0.67 (0.05-7.79)	0.75		
Time from onset to administration $\leq 7$ days	0.26 (0.10-0.68)	0.006	0.82 (0.02-0.40)	0.002
Treatment				
Heparin	0.97 (0.31-3.00)	0.95		
Any anti-viral drug	3.99 (1.46-10.89)	0.007	6.5 (1.13-37.56)	0.04
Blood test at administration				
Lymphocytes ( $\times 10^3/\mu$ L)	1.07 (0.92-1.24)	0.37		
Platelet ( $\times 10^5/\mu$ L)	1.37 (0.84-2.24)	0.20		
LDH ( $\times 10^2$ U/L)	0.85 (0.66-1.09)	0.19		
CRP (mg/mL)	1.01 (0.92-1.09)	0.91		
KL-6 ( $\times 10^2$ U/mL)	0.91 (0.78-1.06)	0.25		
Procalcitonin (ng/mL)	1.08 (0.13-12.74)	0.83		
Ferritin (ng/mL)	1.15 (0.65-2.03)	0.64		
D-dimer ( $\mu$ g/mL)	0.98 (0.95-1.00)	0.09	0.98 (0.96-1.01)	0.25



It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

Severity

1 or 2	(reference)	(reference)	(reference)	(reference)
3	0.36 (0.04-3.02)	0.35		
4	0.11 (0.01-1.17)	0.07	0.04 (0.002-1.01)	0.05

33 We defined COVID-19 disease severity at administration as follows: severity level 1, hospitalized but  
34 not requiring supplemental oxygen; level 2, hospitalized and requiring supplemental oxygen  $\leq$  4 L per  
35 minute (L/min); severity level 3, hospitalized and requiring oxygen therapy  $\geq$  5 L/min or receiving nasal  
36 high-flow oxygen therapy, non-rebreather, or noninvasive mechanical ventilation; level 4, receiving  
37 invasive mechanical ventilation at administration.

38 BMI, body mass index; CI, Confidence interval; CRP, C-reactive protein; KL-6, Krebs von den Lungen-6;  
39 LDH, lactate dehydrogenase; OR, odds ratio.

40

41

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

42 **Figure Legends**

43 **Figure 1.** Flow chart of patients with COVID-19 with the tocilizumab and baricitinib groups.

44

45 **Figure 2.** Kaplan-Meier estimates of infection-free survival between tocilizumab and baricitinib.

46



